再生元公布二季度业绩与管线更新，Dupixent和EYLEA HD继续驱动增长

AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
Introduction & Market Context
Regeneron Pharmaceuticals (NASDAQ:REGN) presented its second-quarter 2026 corporate update on July 30, 2026, showcasing robust financial performance and significant pipeline progress across its diversified therapeutic portfolio. The presentation revealed total revenues of $4.3 billion and non-GAAP earnings per share of $14.29, marking the company’s second consecutive quarter of double-digit growth on both metrics.
The biotechnology company’s shares recently traded at $704.44, up 1.3% from the previous close of $695.42, as investors digested the strong quarterly results and promising pipeline developments. With approximately 50 clinical programs spanning six therapeutic areas and 15 internally-developed therapies already approved, Regeneron continues to demonstrate the productivity of its science-driven approach.
Quarterly Performance Highlights
The company’s Q2 2026 financial performance was anchored by several key achievements across its commercial portfolio. As illustrated in the following quarterly performance overview, Regeneron delivered strong results while advancing multiple pipeline programs.
Total revenues reached $4.3 billion, representing 17% year-over-year growth, while non-GAAP earnings per share of $14.29 reflected an 11% increase from the prior-year period. The company generated $1.4 billion in free cash flow during the first half of 2026 and ended June with $15.1 billion in cash and marketable securities, net of debt.
Notably, the Sanofi collaboration revenue reached an all-time high of $2.2 billion, with Regeneron’s share of collaboration profits climbing 59% year-over-year to $2.0 billion. A significant milestone was achieved as the company fully repaid the Sanofi antibody development balance as of June 30, 2026, which is expected to drive a meaningful step-up in collaboration revenue beginning in the third quarter.
Dupixent: Continued Expansion and Market Leadership
Dupixent (dupilumab) remained Regeneron’s primary growth engine, with global net sales reaching $6 billion in Q2 2026, representing 38% year-over-year growth on a constant currency basis. The following chart illustrates the drug’s consistent sales trajectory and recent acceleration.
The immunology franchise now serves over 1.5 million patients globally across nine approved indications. Recent approvals include pediatric chronic spontaneous urticaria (CSU) in patients aged 2-11 years, granted by both the FDA and European Commission in April 2026, and allergic fungal rhinosinusitis (AFRS) in the U.S. in February 2026.
Dupixent has established itself as the #1 prescribed biologic among dermatologists, pulmonologists, allergists, and ENTs. U.S. sales in Q2 2026 reached $4.6 billion, with international sales contributing $1.4 billion. The strong momentum from recent launches in respiratory conditions (COPD) and dermatology indications (CSU, bullous pemphigoid) is expected to continue supporting growth, though management indicated the pace may moderate in the second half due to tougher year-over-year comparisons.
The successful repayment of the Sanofi development balance represents a pivotal financial milestone, as shown in the following analysis of launch performance and collaboration dynamics.
EYLEA Franchise Transition Accelerates
The ophthalmology portfolio demonstrated the successful transition from legacy EYLEA to the next-generation EYLEA HD formulation. In Q2 2026, EYLEA HD captured approximately 60% of combined U.S. net product sales, with revenues of $596 million representing 52% year-over-year growth and 27% sequential growth.
The shift in market dynamics is evident, with EYLEA HD’s share of U.S. sales increasing from 34% in Q2 2025 to 59% in Q2 2026, while legacy EYLEA declined from 66% to 41% over the same period. The newer formulation’s growth was driven primarily by 24% quarter-over-quarter higher physician unit demand.
Recent label enhancements have strengthened EYLEA HD’s competitive position, as detailed in the following product profile analysis.
The FDA’s approval of extended dosing intervals, including every-20-week regimens for wet age-related macular degeneration and diabetic macular edema, along with the retinal vein occlusion (RVO) indication, provides physicians with greater flexibility. RVO represented approximately 20% of EYLEA net sales in 2025, making this expansion particularly significant.
Management expects EYLEA HD to post sequential demand growth in the low-to-mid teens during the second half of 2026, while legacy EYLEA is projected to continue declining at a similar rate as patients transition to the newer formulation and biosimilar competition increases.
Oncology Portfolio Gains Momentum
Regeneron’s oncology franchise demonstrated encouraging progress with differentiated launches in both solid tumors and hematologic malignancies. The following overview highlights the strategic positioning of Libtayo and Lynozyfic in their respective markets.
Libtayo (cemiplimab-rwlc) posted global net sales of $489 million in Q2 2026, up 29% year-over-year on a constant currency basis. The PD-1 inhibitor has established strong positions in multiple settings: it is the #2 most prescribed immunotherapy for advanced non-small cell lung cancer in the U.S., capturing approximately 20% of new patient share, and leads the anti-PD-1/L1 therapy class in advanced cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma.
The recent launch in adjuvant CSCC, where Libtayo is the only FDA- and EC-approved treatment and the sole NCCN Category 1 Preferred option, is showing encouraging early uptake. This indication targets more than 10,000 eligible patients in the U.S. and EU, engaging a broader range of treating specialties including medical oncologists, radiation oncologists, Mohs surgeons, and head and neck surgeons.
Lynozyfic (linvoseltamab-gcpt), the company’s BCMA-targeting bispecific antibody for relapsed/refractory multiple myeloma, has achieved accelerated FDA approval and conditional EC approval. The product has enrolled more than 500 institutions in its REMS program and has been added to over 80 formularies, with preferred status at a major institution.
The following competitive analysis illustrates Lynozyfic’s differentiated clinical profile compared to other BCMA bispecifics.
Lynozyfic demonstrated approximately 2x complete response rates compared to other BCMA bispecifics at similar follow-up periods, with a 45% stringent complete response plus complete response rate versus 28% for teclistamab and 26% for elranatamab. Additionally, the product offers a simplified dosing regimen requiring only two days of hospitalization during step-up dosing, compared to six days for teclistamab and three days for elranatamab.
Broad Pipeline Addresses Large Market Opportunities
Regeneron’s research and development engine continues to advance a diverse pipeline targeting substantial commercial opportunities across six therapeutic areas. The following comprehensive pipeline overview shows the breadth of the company’s development programs.
The pipeline spans immunology and inflammation ($50 billion+ market potential), ophthalmology ($15 billion+), oncology and hematology-oncology ($60 billion+), hematology ($15 billion+), cardiovascular and metabolic diseases ($50 billion+), and neurology and rare diseases ($15 billion+).
In immunology, the company is pursuing a multi-pronged approach to sustain leadership beyond Dupixent’s current success. This includes next-generation IL-4/IL-13 opportunities with longer dosing intervals, novel long-acting antibodies with optimized binding properties, and long-acting bispecifics. The allergen-specific antibody programs for cat and birch allergies showed positive Phase 3 results in 2025, with registration-enabling studies expected to initiate in 2026.
Late-Stage Programs Position Near-Term Growth
Several late-stage programs are positioned to deliver significant value over the next few years, as outlined in the following development overview.
Lynozyfic’s comprehensive registrational program in multiple myeloma is underway, with the company pursuing a transformative strategy to establish market share in late-line settings, advance to earlier lines with differentiated regimens, and ultimately prevent disease progression by treating precursor conditions. Initial pivotal data are anticipated starting in 2027. Notably, 100% of evaluable patients (n=21) achieved MRD-negativity in high-risk smoldering multiple myeloma and first-line multiple myeloma with the 200 mg monotherapy dose.
The complement-mediated diseases program, featuring cemdisiran (C5 siRNA) with or without pozelimab (C5 antibody), represents another major near-term opportunity. The following therapeutic strategy overview details the differentiated approaches across four indications.
For generalized myasthenia gravis (gMG), cemdisiran monotherapy submissions have been accepted by both the FDA and EMA, with an FDA decision expected in November 2026 and an EC decision anticipated in the second half of 2027. The Phase 3 trial demonstrated a 2.3-point improvement in MG-ADL score compared to baseline by week 24, with clinically meaningful improvements observed as early as week 2.
The commercial opportunity across complement-mediated diseases is substantial, with the gMG market representing approximately $5.0 billion in 2025 worldwide sales, paroxysmal nocturnal hemoglobinuria (PNH) at $2.5 billion, and geographic atrophy at $1.1 billion. U.S. launches are expected in Q4 2026 for gMG, 2028 for PNH, and 2029 or later for geographic atrophy.
Cemdisiran’s clinical profile offers potential advantages over currently approved advanced therapies for gMG, as illustrated in the following efficacy data and differentiation analysis.
The Factor XI anticoagulation program represents a novel approach to addressing the $20 billion anticoagulation market, which remains underpenetrated due to bleeding risk concerns. Regeneron’s two differentiated antibodies—cenvacibart and amrecibart—allow for tailored anticoagulation based on patient needs.
Cenvacibart, targeting the Factor XI catalytic domain, optimizes anticoagulation activity with potential for reduced bleeding risk versus standard of care. Amrecibart, targeting the Factor XI A2 domain, further reduces bleeding risk while maintaining comparable anticoagulation. This differentiated approach enables customized treatment for various patient populations, from those requiring maximal anticoagulation (venous thromboembolism, atrial fibrillation DOAC candidates) to those with highest bleeding risk (atrial fibrillation DOAC non-candidates, peripheral artery disease).
Phase 2 results have been encouraging across multiple indications, as shown in the following clinical data summary.
To date, no major bleeding events have been observed in Phase 1 or Phase 2 studies due to cenvacibart or amrecibart. In VTE prevention post-knee replacement surgery, cenvacibart demonstrated a 7% VTE incidence compared to 12% for apixaban and 48% for historical placebo. In a Phase 1 GI bleed study, cenvacibart plus aspirin resulted in only 25% increase in subclinical GI bleeding versus 48% for rivaroxaban plus aspirin.
Strategic Capital Allocation and Infrastructure Investment
Regeneron outlined a disciplined capital allocation strategy focused on maximizing long-term value creation through three pillars: internal investment, business development, and returning capital to shareholders.
The company expects to invest approximately $6 billion in non-GAAP R&D spending in 2026 and has committed more than $9 billion to U.S. manufacturing and R&D infrastructure expansion over the coming years. This substantial internal investment reflects management’s confidence in the productivity of its science-driven approach and proprietary technology platforms.
On the business development front, Regeneron continues to leverage external innovation through strategic collaborations with Alnylam (cemdisiran C5 siRNA), Hansoh Pharma (GLP-1/GIP for obesity), Intellia, Mammoth, and Tessera (gene editing programs), among others. Management emphasized a disciplined approach to external opportunities, stating they are "not opposed to deals, but opposed to overpaying."
For shareholders, the company repurchased approximately $2 billion of shares in the first half of 2026, with $1.2 billion repurchased in Q2 alone. The board authorized a $3 billion share repurchase program in April, with approximately $2.5 billion available for future repurchases as of June 30. A quarterly dividend of $0.94 per share is scheduled for payment on August 31, 2026.
Forward-Looking Statements and 2026 Milestones
Regeneron identified numerous anticipated milestones across its therapeutic areas for the remainder of 2026 and beyond.
In ophthalmology, the FDA decision on EYLEA HD’s pre-filled syringe is expected, along with interim results from the Phase 3 lead-in cohort for cemdisiran with or without pozelimab in geographic atrophy in Q4 2026. The pre-filled syringe approval could further enhance EYLEA HD’s competitive position by improving ease of use for physicians.
For immunology and inflammation, Dupixent received an EC decision for bullous pemphigoid (though the application was subsequently withdrawn) and an FDA decision for AFRS. The company plans to initiate its clinical program for a novel long-acting IL-13 antibody in atopic dermatitis, along with second Phase 3 trials for both birch and cat allergy programs in the second half of 2026.
In cardiovascular and metabolic diseases, Regeneron expects to initiate Phase 3 studies for olatorepatide monotherapy in obesity with and without type 2 diabetes in the second half of 2026, as well as begin clinical development of olatorepatide combined with Praluent (PCSK9 inhibitor). The combination aims to achieve greater than 50% LDL lowering along with weight loss via a convenient weekly injection, addressing a significant unmet need beyond current GLP-1 therapies, which lower LDL-C by less than 10%.
The hematology program expects to report results from the Phase 3 trial of cemdisiran plus pozelimab in PNH in Q4 2026, while also initiating additional Phase 3 studies for the Factor XI antibodies in anticoagulation indications during the second half of the year.
In oncology, the company anticipates Phase 3 results for fianlimab (LAG-3) plus cemiplimab in adjuvant melanoma in Q4 2026. However, management noted that the first-line metastatic melanoma study did not meet its primary endpoint, and first-line advanced NSCLC data do not support advancing to Phase 3, highlighting the inherent risks in drug development.
For neurology and rare diseases, key regulatory decisions are expected for cemdisiran in gMG (November 2026 PDUFA), garetosmab in fibrodysplasia ossificans progressiva (August 2026 PDUFA), and DB-OTO (Otarmeni) for genetic hearing loss, which was recently approved by the FDA under the Commissioner’s National Priority Voucher program.
The presentation emphasized Regeneron’s commitment to following the science and leveraging its integrated genetics, proteomics, and big data capabilities through the Regeneron Genetics Center, which maintains the world’s largest DNA and proteomics-linked healthcare database. This foundation, combined with proprietary technology platforms including VELOCIMMUNE for human antibodies, VELOCI-BI for bispecifics, and comprehensive genetic medicines capabilities (siRNA, gene editing, AAV gene therapy), positions the company to continue delivering breakthrough medicines across multiple therapeutic areas.
With a non-GAAP gross margin of 87% on net product sales and a strong balance sheet, Regeneron appears well-positioned to execute on its broad pipeline while continuing to invest in long-term growth opportunities. The company’s market capitalization of $71.5 billion and price-to-earnings ratio of 16.9 reflect a relatively modest valuation for a high-growth biotechnology company, according to InvestingPro analysis, which rates the company’s financial health as "GREAT."
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.